Patents by Inventor SARAH BRONNER
SARAH BRONNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220127265Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: January 6, 2022Publication date: April 28, 2022Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
-
Patent number: 11247989Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 21, 2018Date of Patent: February 15, 2022Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
-
Patent number: 11168070Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: May 28, 2020Date of Patent: November 9, 2021Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Publication number: 20200399244Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: May 28, 2020Publication date: December 24, 2020Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Patent number: 10696655Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 21, 2018Date of Patent: June 30, 2020Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Publication number: 20190241558Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: November 21, 2018Publication date: August 8, 2019Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
-
Publication number: 20190152949Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: November 21, 2018Publication date: May 23, 2019Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
-
Publication number: 20170333406Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: August 2, 2017Publication date: November 23, 2017Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
-
Patent number: 9763922Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: November 25, 2015Date of Patent: September 19, 2017Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
-
Publication number: 20160158207Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: ApplicationFiled: November 25, 2015Publication date: June 9, 2016Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
-
Publication number: 20140316149Abstract: This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite; under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: ZACHARY K. WICKENS, BILL MORANDI, ROBERT H. GRUBBS, KACPER SKAKUJ, SARAH BRONNER